Navigation Links
ETHEX Corporation Issues Voluntary Nationwide Recall of Prescription Prenatal and Iron Supplements to Wholesale Level
Date:2/3/2009

ST. LOUIS, Feb. 3 /PRNewswire/ -- ETHEX Corporation, a subsidiary of KV Pharmaceutical Company (NYSE: KVa/KVb), is issuing a voluntary nationwide recall of the products identified below (all lots within their expiration dates) at a wholesale level. The Company is taking this action as a precautionary measure, because the products may have been manufactured under conditions that did not sufficiently comply with current Good Manufacturing Practice (cGMP).

Patients who may have these products in their possession should continue to take them in accordance with their prescriptions, as the risk of suddenly stopping needed medications may place patients at risk. Patients should contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using these products, or to obtain replacement medications or prescriptions.

Products Recalled to the Wholesale/Distributor Level:

Prescription Prenatal Vitamin Products:

    Advanced NatalCare(R) Tablets               Advanced-RF NatalCare(R) Tablets
    Cal-Nate(TM) Tablets                         CareNatal(TM) DHA Tablets
    ComBgen Tablets                           ComBiRx(TM)Tablets
    NataCaps Capsules                         NatalCare Gloss Tablets
    NatalCare PIC Tablets                     NatalCare PIC Forte Tablets
    NatalCare Plus Tablets                    NatalCare Rx Tablets
    NatalCare Three Tablets                   NataTab FA Tablets
    NataTab RX Tablets                        NutriNate(R) Chewable Tablets
    NutriSpire(TM) Tablets                       Prenatal MR 90 FE Tablets
    Prenatal MTR w/Selinium Tablets           Prenatal Rx 1 Tablets
    Prenatal Z, Advanced Formula Tablets      Ultra NatalCare Tablets

Prescription Iron Supplement Products:

    Anemagen Caplets                          Anemagen Forte Caplets
    Conison(TM) Capsules                         Fe-Tinic(TM) 150 Forte Capsules

Any wholesaler inquiries related to this action should be addressed to ETHEX Customer Service at 1-800-748-1472, faxed to ETHEX Customer Service at 314-646-3788, or e-mailed to customer-service@ethex.com. Representatives are available Monday through Friday, 8 am to 5 pm CST.

ETHEX Corporation has initiated recall notifications to wholesalers nationwide who received any inventory of the recalled products, with instructions for returning the recalled products.

This recall is being conducted with the knowledge of the U.S. Food and Drug Administration (FDA). At this time, the Company is unable to determine when distribution of these products will resume.

Patients with questions about the recall should call the telephone number above, or contact their healthcare providers. Any adverse reactions experienced with the use of these products should also be reported to FDA's MedWatch Program by phone at 1-800-FDA-1088, by fax at 1-800-FDA-0178, by mail at MedWatch, FDA, 5600 Fishers Lane, Rockville, MD 20852-9787, or on the MedWatch website at www.fda.gov/medwatch.

The recall announcement is posted on www.kvpharmaceutical.com.

About KV Pharmaceutical Company

KV Pharmaceutical Company is a fully integrated specialty pharmaceutical company that develops, manufactures, markets, and acquires technology-distinguished branded and generic/non-branded prescription pharmaceutical products. The Company markets its technology distinguished products through ETHEX Corporation, a national leader in generic pharmaceuticals, and Ther-Rx Corporation, its branded drug subsidiary.


'/>"/>
SOURCE ETHEX Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. ETHEX Corporation Issues Voluntary Nationwide Recall
2. ETHEX Corporation Initiated Nationwide Voluntary Recalls of Specific Lots of Five Generic Products Due to the Potential for Oversized Tablets
3. ETHEX Corporation Voluntarily Recalls Three Lots of Dextroamphetamine Sulfate 5mg Tablets Due to the Potential for Oversized Tablets
4. ETHEX Corporation Voluntarily Recalls a Single Lot of Morphine Sulfate 60 mg Extended Release Tablets Due to the Potential for Oversized Tablets
5. ALSIUS CORPORATION PREPARED TO INVALIDATE ZOLL TEMPERATURE MANAGEMENT PATENTS
6. Techne Corporation Releases Unaudited Second Quarter Results for Fiscal Year 2009
7. Techne Corporation Declares Dividend
8. DURECT Corporation Invites You to Join Its Fourth Quarter 2008 Earnings Conference Call
9. Digirad Corporation Sells Northern California Service Hubs
10. Torchmark Corporation Announces Fourth Quarter 2008 Earnings Release and Conference Call
11. NutriSystem Expands Voluntary United States Recall of Peanut Butter Granola Breakfast Bar to Include Canada Due to Possible Peanut Corporation of America (PCA) Contamination and Potential Health Risk
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/31/2016)... ... 2016 , ... Psoriasis: Targets and Therapy has ... corresponding author Professor Luigi Naldi says “The review in Psoriasis: Targets and Therapy ... the onset and the severity of psoriasis, and negatively influences the response to ...
(Date:5/31/2016)... ... May 31, 2016 , ... More than 80 representatives of the ... and the Prevent Cancer Foundation held an event on National Hepatitis Testing Day outside ... of viral hepatitis, the leading cause of liver cancer. , Foundation leaders and the ...
(Date:5/31/2016)... ... ... Twenty years ago it was revolutionary: enabling the people who hear distressing voices to ... this approach has proven transformative, both for people who hear voices and for the ... used around the world, but it still lags in the United States. , Now, ...
(Date:5/31/2016)... , ... May 31, 2016 , ... ... calls back to particular advertising campaigns, to monitor the performance of sales and ... can maximize conversions and revenue. The software allows customers to record, transcribe, route, ...
(Date:5/31/2016)... ... May 31, 2016 , ... Like jewels in a crown, the multiple awards ... is home to Ontario’s leading day spa and one of Canada’s few accredited 5 ... a unique concept to combine spa services with hair and beauty services ...
Breaking Medicine News(10 mins):
(Date:5/30/2016)... 30, 2016 According ... Biometrics Market by Technology (Single-factor (Fingerprint, Face, ... Application (Workforce Management), End User (Hospitals, Healthcare ... by MarketsandMarkets, the market is projected to ... USD 1,182.6 Million by 2016, at a ...
(Date:5/30/2016)... - DCGI grants limited approval to market Stempeucel® product for ... Stempeucel® becomes 5th off-the-shelf Stem cell product to be approved by ... Disease (also known as Thromboangiitis Obliterans) is a major unmet medical ... - Prevalence of Buerger,s Disease is estimated to be 1,000,000 in ... the European Community & USA ...
(Date:5/27/2016)... LabStyle Innovations Corp . ( ... today announced that the Company,s Chief Financial Officer, Zvi ... held June 1-2 in New York, NY ... in Los Angeles, CA. ... operational milestones, including the U.S. FDA Clearance and commercial launch ...
Breaking Medicine Technology: